CNTX

Context Therapeutics Inc.
CAPPED RATING

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Context Therapeutics Inc. (CNTX) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (F). The rating has held at C- for 9 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
B+
Factor Score 3.7 / 5.0
Growth
C-
Factor Score 1.9 / 5.0
Profitability
D+
Factor Score 1.6 / 5.0
Momentum
F
Factor Score 0.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.4
EV / EBITDA 0.5
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -60.2%
Price Return 12M -83.3%
Catalyst Signal 0.00
Market Cap $17.2M
TTM Revenue N/A
Price / Sales N/A
ROE -76.1%

Historical Factor Score Progression

Held C- for 9 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B+ (3.7) C- (1.9) D+ (1.6) F (0.7) C+ (2.6) C- (2.1)
2026-11-04 B+ (3.7) C- (1.9) D+ (1.6) F (0.5) C+ (2.7) C- (2.1)
2026-10-28 B+ (3.7) D+ (1.8) D+ (1.6) F (0.6) C+ (2.7) C- (2.1)
2026-10-21 B+ (3.7) D+ (1.8) D+ (1.6) F (0.6) C+ (2.6) C- (2.1)
2026-10-14 B+ (3.7) D+ (1.8) D+ (1.6) F (0.7) C+ (2.6) C- (2.1)
Page 1 of 4